Biogen Turns In Robust Quarter, Fueled By Avonex; Late-Stage Commercial Catalysts Abound
This article was originally published in The Pink Sheet Daily
Executive Summary
In the second quarter, Biogen demonstrated a continuing ability to milk revenue from established MS products while it prepares to launch a wave of potentially market-shifting NMEs.
You may also be interested in...
AstraZeneca Taps Regulus For microRNA Drug Development
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
With Third Quarter Results, Biogen Idec Continues to Ride Its Warhorse Avonex
Q3 results were strong, thanks to Avonex, but new competition from Novartis' oral MS therapy Gilenya and dwindling Rituxan royalties from Roche threaten longer-term outlook.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.